254 related articles for article (PubMed ID: 34374937)
1. CD19 + CD21
Wilfong EM; Vowell KN; Bunn KE; Rizzi E; Annapureddy N; Dudenhofer RB; Barnado A; Bonami RH; Johnson JE; Crofford LJ; Kendall PL
Clin Exp Med; 2022 May; 22(2):209-220. PubMed ID: 34374937
[TBL] [Abstract][Full Text] [Related]
2. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
Front Immunol; 2020; 11():1990. PubMed ID: 33013852
[TBL] [Abstract][Full Text] [Related]
3. CD32 (FcγRIIB) expression is low on CD21
Kourkouni E; Tsiogkas SG; Mavropoulos A; Simopoulou T; Katsiari CG; Bogdanos DP; Sakkas LI
Clin Immunol; 2024 May; 262():110195. PubMed ID: 38494058
[TBL] [Abstract][Full Text] [Related]
4. Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis-an exploratory study.
Hamberg V; Sohrabian A; Volkmann ER; Wildt M; Löfdahl A; Wuttge DM; Hesselstrand R; Dellgren G; Westergren-Thorsson G; Rönnelid J; Andréasson K
Arthritis Res Ther; 2023 Sep; 25(1):162. PubMed ID: 37667402
[TBL] [Abstract][Full Text] [Related]
5. A Composite Serum Biomarker Index for the Diagnosis of Systemic Sclerosis-Associated Interstitial Lung Disease: A Multicenter, Observational Cohort Study.
Jee AS; Stewart I; Youssef P; Adelstein S; Lai D; Hua S; Stevens W; Proudman S; Ngian GS; Glaspole IN; Moodley YP; Bleasel JF; Macansh S; Nikpour M; Sahhar J; Corte TJ;
Arthritis Rheumatol; 2023 Aug; 75(8):1424-1433. PubMed ID: 36908055
[TBL] [Abstract][Full Text] [Related]
6. Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease.
Valenzi E; Bulik M; Tabib T; Morse C; Sembrat J; Trejo Bittar H; Rojas M; Lafyatis R
Ann Rheum Dis; 2019 Oct; 78(10):1379-1387. PubMed ID: 31405848
[TBL] [Abstract][Full Text] [Related]
7. Mediators of systemic sclerosis-associated interstitial lung disease (SSc-ILD): systematic review and meta-analyses.
Fields A; Potel KN; Cabuhal R; Aziri B; Stewart ID; Schock BC
Thorax; 2023 Aug; 78(8):799-807. PubMed ID: 36261273
[TBL] [Abstract][Full Text] [Related]
8. Netrin-1 Regulates Fibrocyte Accumulation in the Decellularized Fibrotic Sclerodermatous Lung Microenvironment and in Bleomycin-Induced Pulmonary Fibrosis.
Sun H; Zhu Y; Pan H; Chen X; Balestrini JL; Lam TT; Kanyo JE; Eichmann A; Gulati M; Fares WH; Bai H; Feghali-Bostwick CA; Gan Y; Peng X; Moore MW; White ES; Sava P; Gonzalez AL; Cheng Y; Niklason LE; Herzog EL
Arthritis Rheumatol; 2016 May; 68(5):1251-61. PubMed ID: 26749424
[TBL] [Abstract][Full Text] [Related]
9. Peripheral blood leucocyte telomere length is associated with progression of interstitial lung disease in systemic sclerosis.
Liu S; Chung MP; Ley B; French S; Elicker BM; Fiorentino DF; Chung LS; Boin F; Wolters PJ
Thorax; 2021 Dec; 76(12):1186-1192. PubMed ID: 34272332
[TBL] [Abstract][Full Text] [Related]
10. Up-regulated expression of HLA-DRB5 transcripts and high frequency of the HLA-DRB5*01:05 allele in scleroderma patients with interstitial lung disease.
Odani T; Yasuda S; Ota Y; Fujieda Y; Kon Y; Horita T; Kawaguchi Y; Atsumi T; Yamanaka H; Koike T
Rheumatology (Oxford); 2012 Oct; 51(10):1765-74. PubMed ID: 22723597
[TBL] [Abstract][Full Text] [Related]
11. Integrative analysis of lung molecular signatures reveals key drivers of systemic sclerosis-associated interstitial lung disease.
Jung SM; Park KS; Kim KJ
Ann Rheum Dis; 2022 Jan; 81(1):108-116. PubMed ID: 34380701
[TBL] [Abstract][Full Text] [Related]
12. High serum C-X-C motif chemokine ligand 10 (CXCL10) levels may be associated with new onset interstitial lung disease in patients with systemic sclerosis: evidence from observational, clinical, transcriptomic and in vitro studies.
Al-Adwi Y; Atzeni IM; Doornbos-van der Meer B; van der Leij MJ; Varkevisser RDM; Kroesen BJ; Stel A; Timens W; Gan CT; van Goor H; Westra J; Mulder DJ
EBioMedicine; 2023 Dec; 98():104883. PubMed ID: 37995465
[TBL] [Abstract][Full Text] [Related]
13. miR-155 in the progression of lung fibrosis in systemic sclerosis.
Christmann RB; Wooten A; Sampaio-Barros P; Borges CL; Carvalho CR; Kairalla RA; Feghali-Bostwick C; Ziemek J; Mei Y; Goummih S; Tan J; Alvarez D; Kass DJ; Rojas M; de Mattos TL; Parra E; Stifano G; Capelozzi VL; Simms RW; Lafyatis R
Arthritis Res Ther; 2016 Jul; 18(1):155. PubMed ID: 27377409
[TBL] [Abstract][Full Text] [Related]
14. Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease.
Meier C; Freiburghaus K; Bovet C; Schniering J; Allanore Y; Distler O; Nakas C; Maurer B
Sci Rep; 2020 Dec; 10(1):21912. PubMed ID: 33318574
[TBL] [Abstract][Full Text] [Related]
15. A methodology for exploring biomarker--phenotype associations: application to flow cytometry data and systemic sclerosis clinical manifestations.
Huang H; Fava A; Guhr T; Cimbro R; Rosen A; Boin F; Ellis H
BMC Bioinformatics; 2015 Sep; 16():293. PubMed ID: 26373409
[TBL] [Abstract][Full Text] [Related]
16. Defining genetic risk factors for scleroderma-associated interstitial lung disease : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease.
Stock CJW; De Lauretis A; Visca D; Daccord C; Kokosi M; Kouranos V; Margaritopoulos G; George PM; Molyneaux PL; Nihtyanova S; Chua F; Maher TM; Ong V; Abraham DJ; Denton CP; Wells AU; Wain LV; Renzoni EA
Clin Rheumatol; 2020 Apr; 39(4):1173-1179. PubMed ID: 31916109
[TBL] [Abstract][Full Text] [Related]
17. Incidence Rate and Prevalence of Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease in Japan: Analysis Using Japanese Claims Databases.
Kuwana M; Saito A; Sakamoto W; Raabe C; Saito K
Adv Ther; 2022 May; 39(5):2222-2235. PubMed ID: 35316503
[TBL] [Abstract][Full Text] [Related]
18. Comorbidity and mortality in systemic sclerosis and matched controls: Impact of interstitial lung disease. A population based cohort study based on health registry data.
Knarborg M; Hyldgaard C; Bendstrup E; Davidsen JR; Løkke A; Shaker SB; Hilberg O
Chron Respir Dis; 2023; 20():14799731231195041. PubMed ID: 37596992
[TBL] [Abstract][Full Text] [Related]
19. Procollagen Type I and III Aminoterminal Propeptide Levels and Severity of Interstitial Lung Disease in Mexican Women With Progressive Systemic Sclerosis.
Gonzalez-Lopez L; Rocha-Muñoz AD; Olivas-Flores EM; Garcia-Gonzalez A; Peguero-Gómez AR; Flores-Navarro J; Villa-Manzano AI; Zavaleta-Muñiz SA; Salazar-Paramo M; Mejía M; Juárez-Contreras P; Vazquez-Del Mercado M; Cardona-Muñoz EG; Trujillo-Hernández B; Nava-Zavala AH; Gamez-Nava JI
Arch Bronconeumol; 2015 Sep; 51(9):440-8. PubMed ID: 25301411
[TBL] [Abstract][Full Text] [Related]
20. Interstitial Lung Disease in Systemic Sclerosis: A Single-center Retrospective Analysis.
Yayla ME; Balcı G; Torgutalp M; Eroğlu DŞ; Dinçer ABK; Gülöksüz EGA; Sezer S; Yüksel ML; Ateş A; Turgay TM; Kınıklı G
Curr Rheumatol Rev; 2022; 18(2):150-156. PubMed ID: 34517806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
